Biogen's reported earnings for Q4 2023 were below market expectations, which typically leads to a negative reaction in the stock market. Additionally, the company's guidance for 2024 suggests that it does not expect a quick recovery or significant growth, further dampening investor sentiment. Given the direct impact of earnings reports and future guidance on stock prices, it's likely that Biogen's shares will experience short-term downward pressure.